The antipsychotic effects of sigma drugs

Neurotransmitter Receptors in Actions of Antipsychotic Medications

Volumn , Issue , 2000, Pages 137-152

  Frieboes, Ralf Michael ^a   Steiger, Axel ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 72049090724     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (81)

1. Martin, W.R., Eades, C.G., Thompson, J.A., Huppler, R.E., and Gilbert, P.E., The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog, J. Pharmacol. Exp. Ther., 197, 517, 1976.
2. Haerzten, C.A., Subjective effects of narcotic antagonists cyclazocine and nalorphine on the addiction research center inventory, Psychopharmacology, 18, 366, 1970.
3. Brady, K. T, Balster, R.L., and May, E.L., Stereoisomers of N-allylnormetazocine: phencyclidinelike behavioral effects in squirrel monkeys and rats, Science, 8, 215, 1982.
4. Martin, B.R., Katzen, J.S., Woods, J.A., Tripathi, H.L., Harris, L.S., and May, E.L., Stereoisomers of [3H]-N-allylnormetazocine bind to different sites in mouse brain, J. Pharmacol. Exp. Ther., 213, 539, 1984.
5. Su, T.P., Evidence for sigma opioid receptor: binding of [3H]SKF 10047 to etorphine-inaccesible sites in guinea-pig brain, J. Pharmacol. Exp. Ther., 223, 284, 1982.
6. Khazan, N., Young, G.A., El-Fakany, E.E., Hong, O., and Calligaro, D., Sigma receptors mediated the psychotomimetic efforts of N-allylnormetazocine (SKF 1007), but not its opioid agonistic properties, Neuropharmacology, 23, 983, 1984.
7. Tam, S.W., Naloxone-inaccessible sigma receptor in rat central nervous system, Proc. Natl. Acad. Sci. U.S.A., 80, 6703, 1983.
8. Vaupel, D.B., Naltrexone falls to antagonize the σ effects of PCP and SKF 10047 in the dog, Eur. J. Pharmacol., 92, 269, 1983.
9. Quirion, R., Hammer, R.P., Herkenham, M., and Pert, C.B., Phencyclidine (angel dust)/sigma “opiate” receptor: visualization by tritium-sensitive film, Proc. Natl. Acad. Sci. U.S.A., 78, 5881, 1981.
10. Contreras, P.C., Quirion, R., and O’Donohue, T.L., Agonistic and antagonistic effects of PCP-derivatives and sigma opioids in PCP behavioral and receptor assays, National Institute on Drug Abuse Res. Monogr., 64, 80, 1986.
11. Largent, B.L., Gundlach, A.L., and Snyder, S.H., Pharmacological and autoradiographic discrimination of sigma and phencyclidine receptor binding sites in brain with (+)-[3H]SKF 10,047, (+)-[3H]-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine and [3H]-1-[1-(2-thienyl)cyclohexyl]piperidine, J. Pharmacol. Exp. Ther., 238, 739, 1986.
12. Dahmen, N., Fischer, V., Hodl, P., Rujescu, D., Reuss, S., Bartoszyk, G.D., and Hiemke, C., Induction of c-fos gene expression by the selective sigma receptor ligand EMD 57445 in rat brain, Eur. Neuropsychopharmacol., 6, 237, 1996.
13. Mash, D.C. and Zabetian, C.P., Sigma receptors are associated with cortical limbic areas in the primate brain, Synapse, 12, 195, 1992.
14. Ishiwata, K., Noguchi, J., Ishii, S., Hatano, K., Ito, K., Nabeshima, T., and Senda, M., Synthesis and preliminary evaluation of [11C]NE-100 labeled in two different positions as a PET sigma receptor ligand, Nucl. Med. Biol., 25, 195, 1998.
15. Itzhak, Y. and Stein, I., Sigma-binding sites in the brain - an emerging concept for multiple sites and their relevance for psychiatric disorders, Life Sci., 47, 1073, 1990.
16. Su, T.P., Sigma receptors. Putative links between nervous, endocrine and immune systems, Eur. J. Biochem., 200, 633, 1991.
17. Wolfe, S.A. and De Souza, E.B., Role of sigma binding sites in the modulation of endocrine and immune functions, in Sigma Receptors, Itzhak, Y., Ed., Academic Press, London, 1994, 287.
18. Bouchard, P., Maurice, T., St. Pierre, S., Privat, A., and Quirion, R., Neuropeptide Y and the calcitonin gene-related peptide attenuate learning impairments induced by MK-801 via a sigma receptor-related mechanism, Eur. J. Neurosci., 9, 2142, 1997.
19. Couture, S. and Debonnel, G., Modulation of the neuronal response to N-methyl-D-aspartate by selective sigma(2) ligands, Synapse, 29, 62, 1998.
20. Liang, X. and Wang, R.Y., Biphasic modulatory action of the selective sigma receptor ligand SR 31742A on N-methyl-D-aspartate-induced neuronal responses in the frontal cortex, Brain Res., 5, 208, 1998.
21. Chaki, S., Okuyama, S., Ogawa, S., and Tomisawa, K., Regulation of NMDA-induced [H-3]dopamine release from rat hippocampal slices through sigma-1 binding sites, Neurochem. Int., 33, 29, 1998.
22. Ault, D.T. and Werling, L.L., Neuropeptide Y-mediated enhancement of NMDA-stimulated [3H]dopamine release from rat prefrontal cortex is reversed by sigma1 receptor antagonists, Schizopr. Res., 31, 27, 1998.
23. Wolfe, S.A., Culp, S.G., and Desouza, E.B., Sigma-receptors in endocrine organs - identification, characterization, and autoradiographic localization in rat pituitary, adrenal, testis, and ovary, Endocrinology, 124, 1160, 1989.
24. Song, C. and Leonard, B.E., Comparison between the effects of sigma receptor ligand JO 1784 and neuropeptide Y on immune functions, Eur. J. Pharmacol., 345, 79, 1998.
25. Frieboes, R.M., Murck, H., Antonijevic, I.A., Kraus, T., Hinze-Selch, D., Pollmächer, T., and Steiger, A., Characterization of the sigma ligand panamesine, a potential antipsychotic by immune response in patients with schizophrenia and by sleep-EEG changes in normal controls, Psychopharmacology, 141, 107, 1999.
26. Wolfe, S.A. and De Souza, E.B., Sigma and phencyclidine receptors in the brain-endocrine-immune axis, National Institute on Drug Abuse Res. Monogr., 133, 95, 1993.
27. Bagetta, G., De Sarro, G.B., Sakurada, S., Rispoli, V., and Nistico, G., Different profile of electrocortical power spectrum changes after micro-infusion into the locus coeruleus of selective agonists at various opioid receptor subtypes in rats, Br. J. Pharmacol., 101, 655, 1990.
28. Aston-Jones, G. and Bloom, F.E., Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle, J. Neurosci., 1, 876, 1981.
29. Young, G.A., Hudson, G.M., Stamidis, H., and Steinfels, G.F., Interactions between U-50,488H and sigma receptor antagonists: EEG, EEG power spectral and behavioral correlates, Eur. J. Pharmacol., 231, 473, 1993.
30. Yamamoto, J., Cortical and hippocampal EEG power spectra in animal models of schizophrenia produced with methamphetamine, cocaine, and phencyclidine, Psychopharmacology, 131, 379, 1997.
31. Wetter, T.C., Lauer, C.J., Gillich, G., and Pollmächer, T., The electroencephalographic sleep pattern in schizophrenic patients treated with clozapine or classical antipsychotic drugs, J. Psychiatr. Res., 30, 411, 1996.
32. Hinze-Selch, D., Mullington, J., Orth, A., Laucer, C.J., and Pollmächer, T., Effects of clozapine on sleep: a longitudinal study, Biol. Psychiatry, 42, 260, 1997.
33. Ganguli, R., Brar, J.S., Chengappa, K.N., Yang, Z.W., Nimgaonkar, V.L., and Rabin, B.S., Autoimmunity in schizophrenia: a review of recent findings, Ann. Med., 25, 489, 1993.
34. Obál, F., Jr., Opp, M., Sary, G., and Krueger, J.M., Endocrine mechanisms in sleep regulation, in Endogenous Sleep Factors, Inoué, S. and Krueger, J.M., Eds., SPB Academic Publishing bv, The Hague, 1990, 109.
35. Krueger, J.M. and Obál, F., Jr., Growth hormone-releasing hormone and interleukin-1 in sleep regulation, FASEB J., 7, 645, 1993.
36. Frieboes, R.M., Murck, H., Wiedemann, K., Holsboer, F., and Steiger, A., Open clinical trial on the sigma ligand panamesine in patients with schizophrenia, Psychopharmacology, 132, 82, 1997.
37. Lauer, C.J., Schreiber, W., Pollmächer, T., Holsboer, F., and Krieg, J.C., Sleep in schizophrenia: a polysomnographic study on drug-naive patients, Neuropsychopharmacology, 16, 51, 1997.
38. Brady, K.T., Balster, R.L., and May, E.L., Stereoisomers of N-allylnormetazocine: phencyclidinelike behavioral effects in squirrel monkeys and rats, Science, 215, 178, 1982.
39. Ogawa, S., Okuyama, S., Araki, H., and Otomo, S., Effect of NE-100, a novel sigma receptor ligand, on phencyclidine-induced cognitive dysfunction, Eur. J. Pharmacol., 263, 9, 1994.
40. Okuyama, S., Imagawa, Y., Ogawa, S., Araki, H., Ajima, A., Tanaka, M., Muramatsu, M., Nakazato, A., Yamaguchi, K., Yoshida, M., et al., NE-100, a novel sigma receptor ligand: in vivo tests, Life Sci., 53, PL 285-PL 290, 1993.
41. Rückert, N.G. and Schmidt, W.J., The sigma receptor ligand 1,3-di-(2-tolyl)guanidine in animal models of schizophrenia, Eur. J. Pharmacol., 233, 261, 1993.
42. Weiner, I., Traub, A., Rawlins, J., Smith, A., and Feldon, J., The sigma ligand BMY-14802 as a potential antipsychotic: evidence from the latent inhibition model in rats, Behav. Pharmacol., 6, 46, 1995.
43. Allen, R.M. and Young, S.J., Phencyclidine-induced psychosis, Am. J. Psychiatry, 135, 1081, 1978.
44. Quirion, R., Chicheportiche, R., Contreras, P., Johnson, K., Lodge, D., Tam, S., Woods, J., and Zukin, S., Classification and nomenclature of phencyclidine and sigma receptor sites, Trends Neurosci., 10, 444, 1987.
45. Bunney, B.G., Bunney, W.E., and Carlsson, A., Schizophrenia and glutamate, in Psychopharmacology: The 4th Generation of Progress, Bloom, F.E. and Kupfer, D.J., Eds., Raven Press, New York, 1995, 1205.
46. Grunze, H.C., Rainnie, D.G., Hasselmo, M.E., Barkai, E., Hearn, E.F., McCarley, R.W., and Greene, R.W., NMDA-dependent modulation of CA1 local circuit inhibition, J. Neurosci., 16, 2034, 1996.
47. Ishiguro, H., Ohtsuki, T., Toru, M., Itokawa, M., Aoki, J., Shibuya, H., Kurumaji, A., Okubo, Y., Iwawaki, A., Ota, K., Shimizu, H., Hamaguchi, H., and Arinami, T., Association between polymorphisms in the type 1 sigma receptor gene and schizophrenia, Neurosci. Lett., 257, 45, 1998.
48. Tam, S.W. and Cook, L., Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes, Proc. Natl. Acad. Sci. U.S.A., 81, 5618, 1984.
49. Weber, E., Sonders, M., Quarum, M., McLean, S., Pou, S., and Keana, J.F., 1,3-Di(2-[5-3H]tolyl)guanidine: a selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs, Proc. Natl. Acad. Sci. U.S.A., 83, 8784, 1986.
50. Bartoszyk, G.D., Bender, H.M., Hellmann, J., Schnorr, C., and Seyfried, C.A., EMD 57445: a selective sigma receptor ligand with the profile of an atypical neuroleptic, Central Nerv. Syst. Drug Rev., 2, 175, 1996.
51. Largent, B.L., Wikstrom, H., Gundlach, A.L., and Snyder, S.H., Structural determinants of sigma receptor affinity, Mol. Pharmacol., 32, 772, 1987.
52. Debonnel, G., Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry, J. Psychiatry Neurosci., 18, 157, 1993.
53. Skuza, G., Golembiowska, K., and Wedzony, K., Effect of EMD 57445, the selective sigma receptor ligand, on the turnover and release of dopamine, Pol. J. Pharmacol., 50, 61, 1998.
54. Gonzalez, G.M. and Werling, L.L., Release of [3H]dopamine from guinea pig striatal slices is modulated by sigma1 receptor agonists, Naunyn Schmiedebergs Arch. Pharmacol., 356, 455, 1997.
55. Lidow, M.S., Williams, G.V., and Goldman-Rakic, P.S., The cerebral cortex: a case for a common site of action of antipsychotics, Trends Pharm. Sci., 19, 136, 1998.
56. Weissman, A.D., Casanova, M.F., Kleinman, J.E., London, E.D., and De Souza, E.B., Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia, Biol. Psychiatry, 29, 41, 1991.
57. Itzhak, Y. and Alerhand, S., Differential regulation of sigma and PCP receptors after chronic administration of haloperidol and phencyclidine in mice, FASEB J., 3, 1868, 1989.
58. Reynolds, G.P., Brown, J.E., and Middlemiss, D.N., [3H]ditolylguanidine binding to human brain sigma sites is diminished after haloperidol treatment, Eur. J. Pharmacol., 194, 235, 1991.
59. Tang, S.W., Helmeste, D.M., Fang, H., Li, M., Vu, R., Bunney, W., Potkin, S., and Jones, E.G., Differential labeling of dopamine and sigma sites by [H-3]nemonapride and [H-3]raclopride in postmortem human brains, Brain Res., 765, 7, 1997.
60. Ferris, R.M., Tang, F.L.M., Chang, K.J., and Russel, A., Evidence that evidence that the potential antipsychotic agent rimcazole (BW U-234) is a specific, competitive antagonist of sigma-sites in brain, Life Sci., 38, 2329, 1986.
61. Davidson, J., Miller, R., Wingfield, M., Zung, W., and Dren, A.T., The first clinical study of BW-234U in schizophrenia, Psychopharmacol. Bull., 18, 173, 1982.
62. Chouinard, G. and Annable, L., An early phase-II clinical trial of BW234U in the treatment of acute schizophrenia in newly admitted patients, Psychopharmacology, 84, 282, 1984.
63. Munetz, M.R., Schulz, S.C., Bellin, M., and Harty, I., Rimcazole (BW234U) in the maintenance treatment of outpatients with schizophrenia, Drug Dev. Res., 16, 79, 1989.
64. Borison, R.L., Pathiraja, A.P., and Diamond, B.I., Clinical efficacy of sigma antagonists in schizophrenia, in Novel Antipsychotic Drugs, Meltzer, H.Y., Ed., Raven Press, New York, 1992, 203.
65. Gewirtz, G.R., Gorman, J.M., Volavka, J., Macaluso, J., Gribkoff, G., Taylor, D.P., and Borison, R., BMY 14802, a sigma receptor ligand for the treatment of schizophrenia, Neuropsychopharmacology, 10, 37, 1994.
66. Tam, S.W., Steinfels, G.F., Gilligan, P.J., Schmidt, W.K., and Cook, L., DuP 734 [1-(cyclopropylmethyl)-4-(2'(4''-fluorophenyl)-2'-oxoethyl)piperidine HBr], a sigma and 5-hydroxytryptamine 2 receptor antagonist: receptor-binding, electrophysiological and neuropharmacological profiles, J. Pharmacol. Exp. Ther., 263, 1167, 1992.
67. Rominger, C. and Tam, S.W., The sigma receptor antagonist antipsychotic DuP 734 preferentially increased dopamine turnover in the frontal cortex in rat brains, Soc. Neurosci. Abstr., 17, 333, 1991.
68. Cook, L., Tam, S.W., and Rohrbach, K.W., DuP 734 [1-(cyclopropylmethyl)-4-(2'(4“fluorophenyl)-2'-oxoethyl)piperidine HBr], a potential antipsychotic agent: preclinical behavioral effects, J. Pharmacol. Exp. Ther., 263, 1159, 1992.
69. Gründer, G., Müller, M., Schlegel, S., Andreas, J., Wetzel, H., Schlösser, R., Eissner, D., and Benkert, O., Treatment of schizophrenia with the sigma ligand EMD 57445: high degree of striatial D2-like dopamine receptor occupancy without extrapyramidal side effects, Pharmacopsychiatry, 30, 172, 1997.
70. Hirsch, S.R. and Barnes, T.R.E., Testing the efficacy of new neuroleptic drugs, in Methodology of the Evaluation of Psychotropic Drugs, Benkert, O., Maier, W., and Rickels, K., Eds., Springer, Berlin, 1990, 26.
71. Huber, M.T., Gotthardt, U., Schreiber, W., and Krieg, J.C., Efficacy and safety of the sigma receptor ligand EMD 57445 (Panamesine) in patients with schizophrenia: an open clinical trial, Pharmacopsychiatry, 32, 68, 1999.
72. Coughenour, L.L. and Cordon, J.J., Characterization of haloperidol and trifluperidol as subtypeselective N-methyl-D-aspartate (NMDA) receptor antagonists using [H-3]TCP and [H-3]ifenprodil binding in rat brain membranes, J. Pharmacol. Exp. Ther., 280, 584, 1997.
73. Modell, S., Naber, D., and Holzbach, R., Efficacy and safety of an opiate sigma-receptor antagonist (SL 82.0715) in schizophrenic patients with negative symptoms: an open dose-range study, Pharmacopsychiatry, 29, 63, 1996.
74. Guitart, X. and Farre, A.J., The effects of E-5842, a sigma receptor ligand and potential atypical antipsychotic, on Fos expression in rat forebrain, Eur. J. Pharmacol., 363, 127, 1998.
75. Pollmächer, T., Hinze-Selch, D., and Mullington, J., Effects of clozapine on plasma cytokine and soluble cytokine receptor levels, J. Clin. Psychopharmacol., 16, 403, 1996.
76. Pollmächer, T., Hinze-Selch, D., Fenzel, T., Kraus, T., Schuld, A., and Mullington, J., Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol, Am. J. Psychiatry, 154, 1763, 1997.
77. Gudelsky, G.A. and Nash, J.F., Neuroendocrinological and neurochemical effects of sigma ligands, Neuropharmacology, 31, 157, 1992.
78. Kinon, B.J. and Lieberman, J.A., Mechanisms of action of atypical antipsychotic drugs: a critical analysis, Psychopharmacology, 124, 2, 1996.
79. Toulmond, S., Serrano, A., Benavides, J., and Scatton, B., Prevention by eliprodil (SL-82.0715) of traumatic brain damage in the rat - existence of a large (18-h) therapeutic window, Brain Res., 620, 32, 1993.
80. Sanchez, C., Arnt, J., Costall, B., Kelly, M.E., Meier, E., Naylor, R.J., and Perregaard, J., The selective sigma2-ligand Lu 28-179 has potent anxiolytic-like effects in rodents, J. Pharmacol. Exp. Ther., 283, 1323, 1997.
81. Kamei, H., Kameyama, T., and Nabeshima, T., (+)-SKF-10,047 and dextromethorphan ameliorate conditioned fear stress through the activation of phenytoin-regulated sigma 1 sites, Eur. J. Pharmacol., 299, 21, 1996.